Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: GlobeNewswire
ATLANTA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has entered into a $40 million term loan agreement with Solar Capital Ltd. (NASDAQ:SLRC) (“Solar Capital”). Alimera will use the proceeds of this funding to pay off an existing $35 million term loan along with related fees and expenses, and to provide additional working capital for general corporate purposes. “Working with Solar Capital provides us with a long-term partner and a stable debt facility over the next few years,” said Dan Myers, Alimera’s chief executive officer. “Further, eliminating the restrictive liquidity covenants in our existing loan will unlock more working capital to invest in our business.” “Solar Capital is pleased to provide this financing to support Alimera’s continued commercial growth,” said Anthony Storino, Head
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Luckie & Company Acquires Marbury Creative Group [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
ALIM
Earnings
- 3/7/24 - Miss
ALIM
Sec Filings
- 4/2/24 - Form 4
- 3/13/24 - Form 4
- 3/13/24 - Form 4
- ALIM's page on the SEC website